Pathophysiology and Management of Cerebral Venous Thrombosis

Mariana B. Morais; Diana Aguiar de Sousa

doi:10.1055/a-2518-9103

Hämostaseologie, Table of Contents

Hamostaseologie 2025; 45(04): 324-334
DOI: 10.1055/a-2518-9103

Review Article

Pathophysiology and Management of Cerebral Venous Thrombosis

Mariana B. Morais

¹Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

²Lopes Lab Unit, Gulbenkian Institute for Molecular Medicine, Lisbon, Portugal

,

Diana Aguiar de Sousa

¹Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

²Lopes Lab Unit, Gulbenkian Institute for Molecular Medicine, Lisbon, Portugal

³Neurosciences Department, Stroke Center, Centro Hospitalar Universitário Lisboa Central – ULS São José, Lisbon, Portugal

› Author Affiliations

Abstract

Cerebral venous thrombosis (CVT) is a less common type of stroke that can occur across all age groups but predominantly affects children and young adults. Diagnosis is often challenging due to the nonspecific and variable clinical presentation. The disease course is heterogeneous, with CVT-related parenchymal lesions developing in approximately 50 to 60% of cases. Despite some advancements, significant gaps persist in understanding the pathophysiology of CVT, including the mechanisms underlying brain injury. Anticoagulation is the cornerstone of CVT treatment, but strategies targeting secondary mechanisms of parenchymal damage are still lacking. Here, the current state of the field is briefly reviewed, with the aim to introduce a wide audience (neuroscientists and clinicians alike) to the disease and inform clinical practice and future research.

Keywords

CVT - thrombosis - pathophysiology - parenchymal brain lesion - stroke

Full Text

References

References
1 Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis 2016; 41 (01) 3-14
2 Engbers MJ, van Hylckama Vlieg A, Rosendaal FR. Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost 2010; 8 (10) 2105-2112
3 Ferro JM, Canhão P, Bousser MG, Stam J, Barinagarrementeria F. ISCVT Investigators. Cerebral vein and dural sinus thrombosis in elderly patients. Stroke 2005; 36 (09) 1927-1932
4 Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F. ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004; 35 (03) 664-670
5 Wolberg AS, Aleman MM, Leiderman K, Machlus KR. Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited. Anesth Analg 2012; 114 (02) 275-285
6 Coutinho JM, Ferro JM, Canhão P. et al. Cerebral venous and sinus thrombosis in women. Stroke 2009; 40 (07) 2356-2361
7 Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med 2005; 352 (17) 1791-1798
8 Dentali F, Poli D, Scoditti U. et al; Cerebral Vein Thrombosis International Study Investigators. Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. J Thromb Haemost 2012; 10 (07) 1297-1302
9 Otite FO, Patel S, Sharma R. et al. Trends in incidence and epidemiologic characteristics of cerebral venous thrombosis in the United States. Neurology 2020; 95 (16) e2200-e2213
10 Silvis SM, Middeldorp S, Zuurbier SM, Cannegieter SC, Coutinho JM. Risk factors for cerebral venous thrombosis. Semin Thromb Hemost 2016; 42 (06) 622-631
11 Lauw MN, Barco S, Coutinho JM, Middeldorp S. Cerebral venous thrombosis and thrombophilia: a systematic review and meta-analysis. Semin Thromb Hemost 2013; 39 (08) 913-927
12 Vecht L, Zuurbier SM, Meijers JCM, Coutinho JM. Elevated factor VIII increases the risk of cerebral venous thrombosis: a case-control study. J Neurol 2018; 265 (07) 1612-1617
13 Ken-Dror G, Cotlarciuc I, Martinelli I. et al. Genome-wide association study identifies first locus associated with susceptibility to cerebral venous thrombosis. Ann Neurol 2021; 90 (05) 777-788
14 Cognat E, Crassard I, Denier C, Vahedi K, Bousser MG. Cerebral venous thrombosis in inflammatory bowel diseases: eight cases and literature review. Int J Stroke 2011; 6 (06) 487-492
15 Aguiar de Sousa D, Mestre T, Ferro JM. Cerebral venous thrombosis in Behçet's disease: a systematic review. J Neurol 2011; 258 (05) 719-727
16 Selvi A, Diakou M, Giannopoulos S, Zikou AK, Argyropoulou MI, Kyritsis AP. Cerebral venous thrombosis in a patient with sarcoidosis. Intern Med 2009; 48 (09) 723-725
17 Byrne JV, Lawton CA. Meningeal sarcoidosis causing intracranial hypertension secondary to dural sinus thrombosis. Br J Radiol 1983; 56 (670) 755-757
18 Vidailhet M, Piette JC, Wechsler B, Bousser MG, Brunet P. Cerebral venous thrombosis in systemic lupus erythematosus. Stroke 1990; 21 (08) 1226-1231
19 Wang L, Chen H, Zhang Y. et al. Clinical characteristics of cerebral venous sinus thrombosis in patients with systemic lupus erythematosus: a single-centre experience in China. J Immunol Res 2015; 2015: 540738
20 Narayan D, Kaul S, Ravishankar K. et al. Risk factors, clinical profile, and long-term outcome of 428 patients of cerebral sinus venous thrombosis: insights from Nizam's Institute Venous Stroke Registry, Hyderabad (India). Neurol India 2012; 60 (02) 154-159
21 Zuurbier SM, Lauw MN, Coutinho JM. et al. Clinical course of cerebral venous thrombosis in adult acute lymphoblastic leukemia. J Stroke Cerebrovasc Dis 2015; 24 (07) 1679-1684
22 Alsaid Y, Gulab S, Bayoumi M, Baeesa S. Cerebral sinus venous thrombosis due to asparaginase therapy. Case Rep Hematol 2013; 2013: 841057
23 Couturier MA, Huguet F, Chevallier P. et al. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: the GRAALL experience. Am J Hematol 2015; 90 (11) 986-991
24 Grove WE. Septic and aseptic types of thrombosis of the cavernous sinus report of cases. Arch Otolaryngol 1936; 24 (01) 29-50
25 Tsai LK, Jeng JS, Liu HM, Wang HJ, Yip PK. Intracranial dural arteriovenous fistulas with or without cerebral sinus thrombosis: analysis of 69 patients. J Neurol Neurosurg Psychiatry 2004; 75 (11) 1639-1641
26 Netteland DF, Sandset EC, Mejlænder-Evjensvold M. et al. Cerebral venous sinus thrombosis in traumatic brain injury: a systematic review of its complications, effect on mortality, diagnostic and therapeutic management, and follow-up. Front Neurol 2023; 13: 1079579
27 Zuurbier SM, Arnold M, Middeldorp S. et al. Risk of cerebral venous thrombosis in obese women. JAMA Neurol 2016; 73 (05) 579-584
28 Coutinho JM, Zuurbier SM, Gaartman AE. et al. Association between anemia and cerebral venous thrombosis: case-control study. Stroke 2015; 46 (10) 2735-2740
29 Stolz E, Valdueza JM, Grebe M. et al. Anemia as a risk factor for cerebral venous thrombosis? An old hypothesis revisited. Results of a prospective study. J Neurol 2007; 254 (06) 729-734
30 Sánchez van Kammen M, Aguiar de Sousa D, Poli S. et al; Cerebral Venous Sinus Thrombosis With Thrombocytopenia Syndrome Study Group. Characteristics and outcomes of patients with cerebral venous sinus thrombosis in SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. JAMA Neurol 2021; 78 (11) 1314-1323
31 Taquet M, Husain M, Geddes JR, Luciano S, Harrison PJ. Cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537,913 COVID-19 cases. EClinicalMedicine 2021; 39: 101061
32 Baldini T, Asioli GM, Romoli M. et al. Cerebral venous thrombosis and severe acute respiratory syndrome coronavirus-2 infection: a systematic review and meta-analysis. Eur J Neurol 2021; 28 (10) 3478-3490
33 Krzywicka K, van de Munckhof A, Sánchez van Kammen M. et al. Age-stratified risk of cerebral venous sinus thrombosis after SARS-CoV-2 vaccination. Neurology 2022; 98 (07) e759-e768
34 Aguiar de Sousa D, Romoli M, Sánchez Van Kammen M. et al. Cerebral venous thrombosis in patients with heparin-induced thrombocytopenia a systematic review. Stroke 2022; 53 (06) 1892-1903
35 Dmytriw AA, Song JSA, Yu E, Poon CS. Cerebral venous thrombosis: state of the art diagnosis and management. Neuroradiology 2018; 60 (07) 669-685
36 Kapoor KG, Katz SE, Grzybowski DM, Lubow M. Cerebrospinal fluid outflow: an evolving perspective. Brain Res Bull 2008; 77 (06) 327-334
37 Tong LS, Guo ZN, Ou YB. et al. Cerebral venous collaterals: a new fort for fighting ischemic stroke?. Prog Neurobiol 2018; 163-164: 172-193
38 Claassen JAHR, Thijssen DHJ, Panerai RB, Faraci FM. Regulation of cerebral blood flow in humans: physiology and clinical implications of autoregulation. Physiol Rev 2021; 101 (04) 1487-1559
39 Rhee CJ, da Costa CS, Austin T, Brady KM, Czosnyka M, Lee JK. Neonatal cerebrovascular autoregulation. Pediatr Res 2018; 84 (05) 602-610
40 Unnerbäck M, Ottesen JT, Reinstrup P. Increased intracranial pressure attenuates the pulsating component of cerebral venous outflow. Neurocrit Care 2019; 31 (02) 273-279
41 Potere N, Abbate A, Kanthi Y. et al. Inflammasome signaling, thromboinflammation, and venous thromboembolism. JACC Basic Transl Sci 2023; 8 (09) 1245-1261
42 Schwarz G, Rizzo AC, Di Como M. et al. Exploring thrombus composition in cerebral venous thrombosis: the first case report with initial insights and implications for treatment advancements. Neurol Sci 2024; 45 (05) 2341-2345
43 Chernysh IN, Nagaswami C, Kosolapova S. et al. The distinctive structure and composition of arterial and venous thrombi and pulmonary emboli. Sci Rep 2020; 10 (01) 5112
44 Jin J, Qiao S, Liu J. et al. Neutrophil extracellular traps promote thrombogenicity in cerebral venous sinus thrombosis. Cell Biosci 2022; 12 (01) 114
45 Mullins ME, Grant PE, Wang B, Gonzalez RG, Schaefer PW. Parenchymal abnormalities associated with cerebral venous sinus thrombosis: assessment with diffusion-weighted MR imaging. AJNR Am J Neuroradiol 2004; 25 (10) 1666-1675
46 Coutinho JM, van den Berg R, Zuurbier SM. et al. Small juxtacortical hemorrhages in cerebral venous thrombosis. Ann Neurol 2014; 75 (06) 908-916
47 Miyamoto K, Heimann A, Kempski O. Microcirculatory alterations in a Mongolian gerbil sinus-vein thrombosis model. J Clin Neurosci 2001; 8 (Suppl. 01) 97-105
48 Barboza MA, Mejías C, Colin-Luna J, Quiroz-Compean A, Arauz A. Intracranial venous collaterals in cerebral venous thrombosis: clinical and imaging impact. J Neurol Neurosurg Psychiatry 2015; 86 (12) 1314-1318
49 Yoshimoto Y, Endo M, Mori T, Wakai S. Correlation between venous stump pressure and brain damage after cortical vein occlusion: an experimental study. J Neurosurg 1997; 86 (04) 694-698
50 Schaller B, Graf R, Wienhard K, Heiss WD. A new animal model of cerebral venous infarction: ligation of the posterior part of the superior sagittal sinus in the cat. Swiss Med Wkly 2003; 133 (29-30): 412-418
51 Kurokawa Y, Hashi K, Okuyama T, Uede T. Regional ischemia in cerebral venous hypertension due to embolic occlusion of the superior sagittal sinus in the rat. Surg Neurol 1990; 34 (06) 390-395
52 Schaller B, Graf R, Sanada Y. et al. Hemodynamic changes after occlusion of the posterior superior sagittal sinus: an experimental PET study in cats. AJNR Am J Neuroradiol 2003; 24 (09) 1876-1880
53 Simonson WT, Yuh FY, Tsai AM. et al. Implications for Treatment and Prognosis. Correlation with Venous Pressure Measurements MR Staging of Acute Dural Sinus Thrombosis. Vol 16.; 1021. Accessed February 16, 2025 at: http://www.ajnr.org/content/16/5/
54 Sato S, Toya S, Ohtani M, Kawase T. The effect of sagittal sinus occlusion on blood- brain barrier permeability and cerebral blood flow in the dog. Brain Edema 1985; 978 (70696): 7-34
55 Vosko MR, Röther J, Friedl B, Bültemeier G, Kloss CUA, Hamann GF. Microvascular damage following experimental sinus-vein thrombosis in rats. Acta Neuropathol 2003; 106 (05) 501-505
56 Rashad S, Niizuma K, Sato-Maeda M. et al. Early BBB breakdown and subacute inflammasome activation and pyroptosis as a result of cerebral venous thrombosis. Brain Res 2018; 1699: 54-68
57 Duan J, Leng X, Han Z. et al. Identifying biomarkers associated with venous infarction in acute/subacute cerebral venous thrombosis. Aging Dis 2021; 12 (01) 93-101
58 Aguiar de Sousa D, Pereira-Santos MC, Serra-Caetano A. et al. Blood biomarkers associated with inflammation predict poor prognosis in cerebral venous thrombosis: a multicenter prospective observational study. Eur J Neurol 2021; 28 (01) 202-208
59 Aguiar de Sousa D, Pereira-Santos MC, Serra-Caetano A. et al. Matrix metalloproteinase-9 levels are associated with brain lesion and persistent venous occlusion in patients with cerebral venous thrombosis. Thromb Haemost 2021; 121 (11) 1476-1482
60 Röther J, Waggie K, van Bruggen N, de Crespigny AJ, Moseley ME. Experimental cerebral venous thrombosis: evaluation using magnetic resonance imaging. J Cereb Blood Flow Metab 1996; 16 (06) 1353-1361
61 Röttger C, Bachmann G, Gerriets T. et al. A new model of reversible sinus sagittalis superior thrombosis in the rat: magnetic resonance imaging changes. Neurosurgery 2005; 57 (03) 573-580 , discussion 573–580
62 Frerichs KU, Deckert M, Kempski O, Schürer L, Einhäupl K, Baethmann A. Cerebral sinus and venous thrombosis in rats induces long-term deficits in brain function and morphology – evidence for a cytotoxic genesis. J Cereb Blood Flow Metab 1994; 14 (02) 289-300
63 Srivastava AK, Kalita J, Haris M, Gupta RK, Misra UK. Radiological and histological changes following cerebral venous sinus thrombosis in a rat model. Neurosci Res 2009; 65 (04) 343-346
64 Aguiar de Sousa D, Lucas Neto L, Arauz A. et al. Early recanalization in patients with cerebral venous thrombosis treated with anticoagulation. Stroke 2020; 51 (04) 1174-1181
65 Scerrati A, De Bonis P, Zamboni P. et al. A new insight in nonaneurysmal subarachnoid hemorrhage: the potential role of the internal jugular veins. J Neurol Surg A Cent Eur Neurosurg 2022; 83 (04) 344-350
66 Zhou Y, Wang Y, Wang J, Anne Stetler R, Yang QW. Inflammation in intracerebral hemorrhage: from mechanisms to clinical translation. Prog Neurobiol 2014; 115 (C): 25-44
67 Ding R, Ou W, Chen C. et al. Endoplasmic reticulum stress and oxidative stress contribute to neuronal pyroptosis caused by cerebral venous sinus thrombosis in rats: Involvement of TXNIP/peroxynitrite-NLRP3 inflammasome activation. Neurochem Int 2020; 141: 104856
68 Hu S, Lee H, Zhao H, Ding Y, Duan J. Inflammation and severe cerebral venous thrombosis. Front Neurol 2022; 13: 873802
69 Nagai M, Terao S, Yilmaz G. et al. Roles of inflammation and the activated protein C pathway in the brain edema associated with cerebral venous sinus thrombosis. Stroke 2010; 41 (01) 147-152
70 Srivastava AK, Kalita J, Dohare P, Ray M, Misra UK. Studies of free radical generation by neurons in a rat model of cerebral venous sinus thrombosis. Neurosci Lett 2009; 450 (02) 127-131
71 Wang J, Ji X, Ling F, He X. Comparison of anticoagulation and thrombolysis treatments in a rat model of superior sagittal sinus thrombosis. Int J Neurosci 2014; 124 (07) 532-541
72 Aguiar de Sousa D, Lucas Neto L, Canhão P, Ferro JM. Recanalization in cerebral venous thrombosis a systematic review and meta-analysis. Stroke 2018; 49 (08) 1828-1835
73 Kim DJ, Honig A, Alimohammadi A, Sepehry AA, Zhou LW, Field TS. Recanalization and outcomes after cerebral venous thrombosis: a systematic review and meta-analysis. Res Pract Thromb Haemost 2023; 7 (03) 100143
74 Thorell SE, Parry-Jones AR, Punter M, Hurford R, Thachil J. Cerebral venous thrombosis-a primer for the haematologist. Blood Rev 2015; 29 (01) 45-50
75 Saposnik G, Bushnell C, Coutinho JM. et al; American Heart Association Stroke Council; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Cardiovascular and Stroke Nursing; and Council on Hypertension. Diagnosis and management of cerebral venous thrombosis: a scientific statement from the American Heart Association. Stroke 2024; 55 (03) e77-e90
76 Ferro JM, Bousser MG, Canhão P. et al; European Stroke Organization. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European Academy of Neurology. Eur J Neurol 2017; 24 (10) 1203-1213
77 Sadik JC, Jianu DC, Sadik R. et al. Imaging of cerebral venous thrombosis. Life (Basel) 2022; 12 (08) 1215
78 Yuh WT, Simonson TM, Wang AM. et al. Venous sinus occlusive disease: MR findings. AJNR Am J Neuroradiol 1994; 15 (02) 309-316
79 Bonneville F. Imaging of cerebral venous thrombosis. Diagn Interv Imaging 2014; 95 (12) 1145-1150
80 Lee SK, Hetts SW, Halbach V. et al; Standard and Guidelines Committee for the Society of Neurointerventional Surgery. Standard and guidelines: intracranial dural arteriovenous shunts. J Neurointerv Surg 2017; 9 (05) 516-523
81 Coutinho JM, van de Munckhof A, Aguiar de Sousa D. et al. Reducing the global burden of cerebral venous thrombosis: an international research agenda. Int J Stroke 2024; 19 (06) 599-610
82 Yang X, Yu P, Zhang H. et al. Deep learning algorithm enables cerebral venous thrombosis detection with routine brain magnetic resonance imaging. Stroke 2023; 54 (05) 1357-1366
83 Bushnell C, Saposnik G. Evaluation and management of cerebral venous thrombosis. Continuum (Minneap Minn) 2014; 20 (2 Cerebrovascular Disease): 335-351
84 Einhäupl K, Bousser MG, de Bruijn SFTM. et al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis. Eur J Neurol 2006; 13 (06) 553-559
85 Silvis SM, de Sousa DA, Ferro JM, Coutinho JM. Cerebral venous thrombosis. Nat Rev Neurol 2017; 13 (09) 555-565
86 Misra UK, Kalita J, Chandra S, Kumar B, Bansal V. Low molecular weight heparin versus unfractionated heparin in cerebral venous sinus thrombosis: a randomized controlled trial. Eur J Neurol 2012; 19 (07) 1030-1036
87 de Bruijn SFTM, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke 1999; 30 (03) 484-488
88 Ferro JM, Coutinho JM, Dentali F. et al; RE-SPECT CVT Study Group. Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: a randomized clinical trial. JAMA Neurol 2019; 76 (12) 1457-1465
89 Field TS, Dizonno V, Almekhlafi MA. et al; SECRET Investigators. Study of rivaroxaban for cerebral venous thrombosis: a randomized controlled feasibility trial comparing anticoagulation with rivaroxaban to standard-of-care in symptomatic cerebral venous thrombosis. Stroke 2023; 54 (11) 2724-2736
90 Ma H, Gu Y, Bian T. et al. Dabigatran etexilate versus warfarin in cerebral venous thrombosis in Chinese patients (CHOICE-CVT): an open-label, randomized controlled trial. Int J Stroke 2024; 19 (06) 635-644
91 Yaghi S, Shu L, Bakradze E. et al. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): a multicenter international study. Stroke 2022; 53 (03) 728-738
92 van de Munckhof A, Sánchez van Kammen M, Krzywicka K. et al. Direct oral anticoagulants for the treatment of cerebral venous thrombosis - a protocol of an international phase IV study. Front Neurol 2023; 14: 1251581
93 Lewis W, Saber H, Sadeghi M, Rajah G, Narayanan S. Transvenous endovascular recanalization for cerebral venous thrombosis: a systematic review and meta-analysis. World Neurosurg 2019; 130: 341-350
94 Fan Y, Yu J, Chen H. et al; Chinese Stroke Association Stroke Council CVST Guideline Writing Committee. Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of cerebral venous sinus thrombosis. Stroke Vasc Neurol 2020; 5 (02) 152-158
95 Coutinho JM, Zuurbier SM, Bousser MG. et al; TO-ACT Investigators. Effect of endovascular treatment with medical management vs standard care on severe cerebral venous thrombosis: the TO-ACT randomized clinical trial. JAMA Neurol 2020; 77 (08) 966-973
96 Palazzo P, Agius P, Ingrand P. et al. Venous thrombotic recurrence after cerebral venous thrombosis: a long-term follow-up study. Stroke 2017; 48 (02) 321-326
97 Miranda B, Ferro JM, Canhão P. et al; ISCVT Investigators. Venous thromboembolic events after cerebral vein thrombosis. Stroke 2010; 41 (09) 1901-1906
98 Miranda B, Aaron S, Arauz A. et al. The benefit of EXtending oral antiCOAgulation treatment (EXCOA) after acute cerebral vein thrombosis (CVT): EXCOA-CVT cluster randomized trial protocol. Int J Stroke 2018; 13 (07) 771-774
99 Martinelli I, Bucciarelli P, Passamonti SM, Battaglioli T, Previtali E, Mannucci PM. Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis. Circulation 2010; 121 (25) 2740-2746
100 Aguiar de Sousa D, Canhão P, Ferro JM. Safety of pregnancy after cerebral venous thrombosis: a systematic review. Stroke 2016; 47 (03) 713-718
101 Aguiar de Sousa D, Canhão P, Crassard I. et al; ISCVT-2-PREGNANCY Investigators. Safety of pregnancy after cerebral venous thrombosis: results of the ISCVT (International Study on Cerebral Vein and Dural Sinus Thrombosis)-2 PREGNANCY Study. Stroke 2017; 48 (11) 3130-3133
102 Sader N, de Lotbinière-Bassett M, Tso MK, Hamilton M. Management of venous sinus thrombosis. Neurosurg Clin N Am 2018; 29 (04) 585-594
103 Biousse V, Bruce BB, Newman NJ. Update on the pathophysiology and management of idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry 2012; 83 (05) 488-494
104 Xue X, Zhou C, Gao Y, Ji X, Zhang X. Optic nerve sheath fenestration for visual impairment in cerebral venous diseases. Front Neurol 2023; 14: 1065315
105 Lindgren E, Silvis SM, Hiltunen S. et al. Acute symptomatic seizures in cerebral venous thrombosis. Neurology 2020; 95 (12) e1706-e1715
106 Ferro JM, Canhão P, Bousser MG, Stam J, Barinagarrementeria F. ISCVT Investigators. Early seizures in cerebral vein and dural sinus thrombosis: risk factors and role of antiepileptics. Stroke 2008; 39 (04) 1152-1158
107 Avanali R, Gopalakrishnan MS, Devi BI, Bhat DI, Shukla DP, Shanbhag NC. Role of decompressive craniectomy in the management of cerebral venous sinus thrombosis. Front Neurol 2019; 10 (May): 511
108 Ferro JM, Crassard I, Coutinho JM. et al; Second International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT 2) Investigators. Decompressive surgery in cerebrovenous thrombosis: a multicenter registry and a systematic review of individual patient data. Stroke 2011; 42 (10) 2825-2831
109 Aaron S, Ferreira JM, Coutinho JM. et al; DECOMPRESS2 Study Group. Outcomes of decompressive surgery for patients with severe cerebral venous thrombosis: DECOMPRESS2 observational study. Stroke 2024; 55 (05) 1218-1226
110 Borhani-Haghighi A, Hooshmandi E. Cerebral venous thrombosis: a practical review. Postgrad Med J 2024; 100 (1180): 68-83
111 deVeber G, Andrew M, Adams C. et al. Cerebral sinovenous thrombosis in children. J Engl J Med 2001; 345 (06) 417-423
112 Wasay M, Dai AI, Ansari M, Shaikh Z, Roach ES. Cerebral venous sinus thrombosis in children: a multicenter cohort from the United States. J Child Neurol 2008; 23 (01) 26-31
113 Ranjan R, Ken-Dror G, Sharma P. Pathophysiology, diagnosis and management of cerebral venous thrombosis: a comprehensive review. Medicine (Baltimore) 2023; 102 (48) e36366
114 Yii IYL, Mitchell PJ, Dowling RJ, Yan B. Imaging predictors of clinical deterioration in cerebral venous thrombosis. J Clin Neurosci 2012; 19 (11) 1525-1529
115 Zuurbier SM, Coutinho JM, Stam J. et al; ISCVT Investigators. Clinical outcome of anticoagulant treatment in head or neck infection-associated cerebral venous thrombosis. Stroke 2016; 47 (05) 1271-1277
116 Sharma T, Kamm S. What's new in emergencies, trauma, and shock: prehospital and hyperacute stroke care in India - hurdles we need to cross. J Emerg Trauma Shock 2024; 17 (03) 127-128
117 Dentali F, Ageno W, Rumi E. et al. Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases. Thromb Res 2014; 134 (01) 41-43
118 Koopman K, Uyttenboogaart M, Vroomen PC, van der Meer J, De Keyser J, Luijckx GJ. Long-term sequelae after cerebral venous thrombosis in functionally independent patients. J Stroke Cerebrovasc Dis 2009; 18 (03) 198-202
119 Zuurbier SM, Hiltunen S, Tatlisumak T. et al. Admission hyperglycemia and clinical outcome in cerebral venous thrombosis. Stroke 2016; 47 (02) 390-396
120 Hiltunen S, Putaala J, Haapaniemi E, Tatlisumak T. Long-term outcome after cerebral venous thrombosis: analysis of functional and vocational outcome, residual symptoms, and adverse events in 161 patients. J Neurol 2016; 263 (03) 477-484
121 Bugnicourt JM, Guegan-Massardier E, Roussel M. et al. Cognitive impairment after cerebral venous thrombosis: a two-center study. J Neurol 2013; 260 (05) 1324-1331
122 Sánchez van Kammen M, Lindgren E, Silvis SM. et al. Late seizures in cerebral venous thrombosis. Neurology 2020; 95 (12) e1716-e1723
123 Wei Y, Deng X, Sheng G, Guo XB. A rabbit model of cerebral venous sinus thrombosis established by ferric chloride and thrombin injection. Neurosci Lett 2018; 662: 205-212
124 Wang J, Tan HQ, Li MH. et al. Development of a new model of transvenous thrombosis in the pig superior sagittal sinus using thrombin injection and balloon occlusion. J Neuroradiol 2010; 37 (02) 109-115
125 Nagai M, Yilmaz CE, Kirchhofer D, Esmon CT, Mackman N, Granger DN. Role of coagulation factors in cerebral venous sinus and cerebral microvascular thrombosis. Neurosurgery 2010; 66 (03) 560-565 , discussion 565–566
126 Röttger C, Madlener K, Heil M. et al. Is heparin treatment the optimal management for cerebral venous thrombosis? Effect of abciximab, recombinant tissue plasminogen activator, and enoxaparin in experimentally induced superior sagittal sinus thrombosis. Stroke 2005; 36 (04) 841-846
127 Ferro M, Bettencourt S, Soares M. et al. Predictors and outcome of deterioration during admission in patients with cerebral venous thrombosis. European Stroke Journal 2025